Inhibikase Therapeutics, Inc. [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K	10-K	S-1/A
Net income	-18.1	-14.8	-2.8	-5.7	-2.2
Stock-based compensation				1.4	0.6
Change in working capital [+]	-0.3	-0.2	-0.2	1.2	1.9
Accounts receivable				0.5	-0.3
Accounts payable				0.0	0.6
Deferred revenues		-2.3	0.9
Other	-0.3	2.1	-1.1	0.7	1.6
Other operating activities	1.0	0.7	1.9	2.7	0.3
Cash from operations	-17.4	-14.3	-1.1	-0.3	0.7

Capital expenditures	0.2	0.0	0.0	0.0	0.0
Purchases of property and equipment	0.2
Purchases of short-term investments	20.7
Purchases of short-term investments	20.7
Other cash from investing	-37.0				0.1
Cash from investing	-16.0	0.0	0.0	0.0	0.1

Issuance of common stock, net		41.1	14.8		1.2
Option exercises	0.0	0.1
Other cash from financing	-0.2	0.0	0.3	0.0	-1.6
Cash from financing	-0.2	41.1	15.1	0.0	-0.4

Free cash flow	-17.1	-14.3	-1.1	-0.3	0.7
Per share (diluted)	($0.68)	($0.79)	($0.14)

Cash paid for interest	0.0	0.0	0.0